DOCSLIB.ORG

Levodopa Therapy for Parkinson Disease: a Look Backward and Forward

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Henry Ford Health System

Henry Ford Health System Scholarly Commons

Neurology Articles

4-5-2016

Neurology

Levodopa therapy for Parkinson disease: A look backward and forward

Peter A. LeWitt

Henry Ford Health System, [email protected]

Stanley Fahn

Henry Ford Health System

Follow this and additional works at: https://scholarlycommons.henryford.com/neurology_articles

Recommended Citation

LeWitt PA, and Fahn S. Levodopa therapy for Parkinson disease: A look backward and forward. Neurology 2016; 86(14 Suppl 1):S3-s12.

This Article is brought to you for free and open access by the Neurology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Neurology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.

Levodopa therapy for Parkinson disease

A look backward and forward

Peter A. LeWitt, MD Stanley Fahn, MD

ABSTRACT

Although levodopa is widely recognized as the most effective therapy for Parkinson disease (PD), its introduction 5 decades ago was preceded by several years of uncertainty and equivocal clinical results. The translation of basic neuroscience research by Arvid Carlsson and Oleh Hornykiewicz provided a logical pathway for treating PD with levodopa. Yet the pioneering clinicians who transformed PD therapeutics with this drug—among them Walther Birkmayer, Isamu Sano, Patrick McGeer, George Cotzias, Melvin Yahr, and others—faced many challenges in determining whether the concept and the method for replenishing deficient striatal dopamine was correct. This article reviews highlights in the early development of levodopa therapy. In addition, it provides an overview of emerging drug delivery strategies that show promise for improving levodopa’s pharmacologic limitations. Neurology® 2016;86 (Suppl 1):S3–S12

Correspondence to Dr. LeWitt: [email protected]

GLOSSARY

CNS 5 central nervous system; PD 5 Parkinson disease; TOPA 5 2,4,5-trihydroxyphenylalanine.

Among neurodegenerative diseases, Parkinson disease (PD) is unique in having several highly effective medications for suppressing its signs and symptoms. Heading the list of treatment options over the past 5 decades has been a remarkably effective medication: levodopa (3,4- dihydroxy-L-phenylalanine; also known as L-DOPA).1–3 Its worldwide impact on reversing the disabilities of PD and improving quality of life has been enormous, though it arrived on the therapeutics scene amidst skepticism and, initially, unfulfilled promise.4,5 Eventually, after almost a decade of unconvincing clinical trials, levodopa finally proved itself to be a successful therapy.6,7 It provided the first opportunity for clinician and patient alike to recognize how much of the parkinsonian motor syndrome—resting tremor, slowed movement, decreased dexterity, rigidity, postural disturbance, and other impairments—are reversible consequences of striatal dopaminergic deficiency. Levodopa has also been one of the most cost-effective medications ever developed. Although, after nearly a half-century of use, this medication continues to be an enduring treatment for PD, it also behaves, as pioneering researcher Oleh Hornykiewicz recognized early on, as “.far from perfect as a drug.”8 Levodopa’s limitations at treating the full spectrum of parkinsonian signs and symptoms, as well as declining effectiveness, have been recognized in follow-up of PD populations for 10 years and longer.9
How levodopa came to be developed as a therapy is instructive for the modern reader in that it nicely illustrates a dictum of Louis Pasteur that “chance favors the prepared mind.” In fact, several “prepared minds” lent rational and imaginative thinking to the understanding of the distinctive pathology of the PD brain and how its biochemical changes might be reversed. Highlighting these revolutionary events was the development of an animal model (reserpineinduced akinesia), which was actually more of an analogy to parkinsonism than a rigorous recapitulation of all clinical features. A key part of the research leading to levodopa as a therapy

From the Department of Neurology (P.A.L.), Henry Ford Hospital; Department of Neurology (P.A.L.), Wayne State University School of Medicine, Detroit, MI; and Department of Neurology (S.F.), Columbia University Medical Center, New York, NY. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

This Neurology® supplement was not peer-reviewed. Information contained in this Neurology supplement represents the opinions of the authors. These opinions are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors

of Neurology.

© 2016 American Academy of Neurology

S3

ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

was emerging knowledge about how amino extracted the active ingredient and developed acids could be transferred across the blood–brain its therapeutic use in the 1950s as a powerful barrier (unlike dopamine, which, as a charged antihypertensive agent.15 The attraction of molecule, is excluded). When Carlsson et al.10 reserpine for Carlsson16 was its ability to first found levodopa could reverse the akinesia in deplete brain stores of serotonin. His experireserpinized rabbits, dopamine was regarded as ments with reserpine searched for its effects no more than an intermediate in the catechol- on other neurotransmitters as well. In collaboamine synthesis pathway for norepinephrine and ration with Nils Åke Hillarp, Carlsson found epinephrine. Following that experiment, the that reserpine depleted norepinephrine and epiSwedish neuroscientist and Nobel Prize winner nephrine in the adrenal glands of rabbits.17 Arvid Carlsson11 showed that dopamine was Could this have relevance for neurotransmitters present in the brain, was depleted with reserpine, in the brain? Carlsson endeavored to determine and could be restored with levodopa. Later, as if the tranquilizer effect of reserpine in mice and dopamine’s role in central nervous system rabbits was due to depletion of serotonin or the (CNS) neurotransmission became recognized, catecholamines. In the first of a series of landlevodopa achieved the status of “.the most nat- mark experiments on the brain that explored ural substance.for treating.the striatal dopa- behavioral and neurochemical outcomes, he

  • mine deficiency syndrome.”8
  • studied mice and rabbits rendered immobile

Like the antituberculosis drug D-cycloserine, by reserpine. Carlsson and colleagues discovanother modified amino acid, levodopa lacks ered that this motor impairment could not be the complexity of many drugs used in modern attributed to depleted serotonin.10,18 Adminismedicine. The Swiss biochemist Marcus Gug- tering 5-hydroxytryptophan, the immediate genheim12 isolated levodopa from a natural precursor of serotonin, had no effect on immosource, the broad bean (Vicia faba), and bility. Carlsson had used 5-hydroxytryptohan in characterized this compound in 1913. With his experiments because he was aware that a curiosity as to its biological roles, he heroically charged molecule like serotonin was unable to self-administered a 2.5-g oral dose.12 This cross the blood–brain barrier. Using similar promptly caused nausea and vomiting,12 side reasoning, he next tested racemic 3,4- effects that even today are sometimes experi- dihydroxyphenylalanine, which, as an amino enced by patients. In the 1940s, D,L-3,4- acid, could be transported across the blood– dihydroxyphenylalanine as a racemic mixture brain barrier by means of a sodium-dependent (levodopa is the proper name for just the levo L-stereospecific uptake mechanism.19 In contrast species) was administered to humans in experi- to the absence of effect conferred by the serotoments that investigated its effects on blood nin precursor, D,L-3,4-dihydroxyphenylalanine pressure13 and its metabolism to form dopa- administration rapidly and almost completely mine.14 Even though levodopa can be found in reversed the animal’s inability to move. This trace amounts in the human brain and else- profound (though transient) effect was enhanced where in the body, no other physiologic func- by pretreating the animals with iproniazid, tions have been determined for it. Levodopa a monoamine oxidase inhibitor, supporting lacks a nucleic acid triplet codon and does not “the assumption that the effect of 3,4-

  • find its way into protein formation.
  • dihydroxyphenylalanine was due to an amine

Although this compound was recognized as formed from it.”10 Carlsson developed a sensitive the starting source of catecholamine synthesis, fluorescent assay for dopamine, and his doctoral interest in levodopa as a potential therapy for students were able to demonstrate in the brains PD was nonexistent until after it was utilized of dogs that regional dopamine concentrations in the animal research experiments mentioned were highest in the caudate and putamen (the above by Arvid Carlsson, who was investigating striatum).20 In this region, concentrations of reserpine’s sedative effect. Reserpine, a naturally norepinephrine were only at trace levels.

  • occurring alkaloid compound derived from the
  • The identity of dopamine as a major brain

snakeroot plant, was originally used in tradi- neurotransmitter and integral to motor functional medicine in India. Swiss chemists tion (and subsequently to behavioral function)

S4

Neurology 86 (Suppl 1) April 5, 2016

ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

led to the analogy that depleted dopamine ganglia (where the brain’s highest dopamine concentrations might explain the pathophysi- concentrations were found).11,20

  • ology of PD, which in some respects resem-
  • Next in the pathway for developing dopa-

bled the behavioral deficits of reserpinized minergic therapy of PD were the contribuanimals. At this point, there was no under- tions of Austrian neuropharmacologist Oleh standing of why this might be, especially since Hornykiewicz.26 With an interest in measurnorepinephrine concentrations did not rise ing and understanding the roles of dopamine when levodopa was administered. It required in the striatum, Hornykiewicz wondered another breakthrough, recognition of the reg- whether observations made in reserpinized anulatory step in norepinephrine production imals corresponded to findings in the PD imposed by dopamine-b-hydroxylase in brain. He obtained autopsied brain specimens norepinephrine-synthesizing neurons.21 Once from people who died of PD, postencephalitic this discovery was made, the diversity of cate- parkinsonism, or Huntington disease, and cholamine functions in the brain became bet- without neurologic disease, and measured ter understood as the era of dopaminergic dopamine and norepinephrine in a number therapeutics opened for PD. Ironically, these of brain regions. Ehringer and Hornykiewicz27 developments also ushered in a long period of found a striking loss of dopamine in the parneglect for exploring norepinephrine as a ther- kinsonian brains, in contrast to Huntington

  • apeutic target for PD.22
  • disease and control brain; the loss was partic-

Offering a functional role to dopamine was ularly striking in the striatum, where the doparevolutionary at the time, especially since the mine content reduction was approximately entire pathway of catecholamine synthesis 90%. Further research determined in the starting from phenylalanine and tyrosine had upper brainstem that a small group of pigyet to be worked out (though much earlier, mented neurons, the substantia nigra, also Hermann Blaschko23 identified the steps used had major loss of dopamine.28 A functional in creating epinephrine from levodopa). Recog- connection between the substantia nigra and nizing the role of dopamine and the simplicity striatum was subsequently recognized by hisby which its function could be restored by levo- tochemical imaging of axonal projections that dopa administration marked a turning point in extend between these regions.29

  • the eventual discoveries that led to harnessing
  • The therapeutic dimensions of these discov-

this drug for the treatment of PD. The variable eries soon became obvious to Hornykiewicz, and inconclusive initial clinical results, how- who collaborated with Austrian geriatrician ever, led to this idea being largely unaccepted Walther Birkmayer to undertake clinical trials by many neurologists.4,5 A number of scientific with L-3,4-dihydroxyphenylalanine. This was questions remained unsettled. Many neuro- given IV in acute experiments to patients with scientists raised concerns that dopamine did PD and those with parkinsonism due to von not meet established criteria for a neurotrans- Economo encephalitis. These clinical trials, mitter and felt it was merely a precursor for which were initiated in mid-1961, involved a the other catecholamines. Furthermore, high group of 20 patients who received levodopa at dosage of levodopa was suspected to be a pos- doses between 50 and 150 mg.30 In some insible neurotoxin (and responsible for killing stances, there were striking results, with marked some of the animals in some experiments).24 improvements in mobility for some of the paAlthough tyrosine was suspected to be the tients who had long been bedridden or unable endogenous source for levodopa, the enzyme to walk.26 The benefits became evident quickly responsible for this synthesis was not known. following the injections, and for some of the The rate-limiting step, tyrosine hydroxylase, patients, lasted for up to 24 hours. Unknown was finally identified in 1964.25 It was largely to these investigators were similar experiments Carlsson’s work eventually convining neuro- that had been conducted 1 year earlier by a scientists that dopamine behaved as a neuro- research group in Japan led by Isamu Sano. transmitter in brain, subserving many of the Their clinical experiment followed a similar motor activities mediated through the basal logic to the work of Carlsson, Hornykiewicz,

Neurology 86 (Suppl 1) April 5, 2016

S5

ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

and Birkmayer, in that they capitalized on their some reduction in clinical signs and symptoms own findings that dopamine concentrations in (such as impaired speech or posture), the rethe brain were greatest in several basal ganglia maining 30% were judged not to have experiregions.31 Since they also determined that stri- enced any improvements.

  • atal dopamine concentration in an autopsied
  • The first to use high oral dosages of D,L-3,4-

PD brain was very much diminished, Sano32 dihydroxyphenylalanine in patients with PD went on to conduct a trial of racemic 3,4- were the Canadian neuropharmacologist Patdihydroxyphenylalanine. In this study, the 5 rick McGeer and neurologist Ludmila Zeldopatients who received 200 mg IV demonstrated wicz in 1964.40 Starting with doses of 250 mg/ what the researchers described as minimal im- d, they built up the dose gradually by increprovements of rigidity and tremor. The report ments of 250 mg/d until a daily dosage of 5 g/ of the study did not receive attention outside of d was reached. They treated 10 patients (6 PD, Japan at the time and, presumably because of 3 postencephalitic parkinsonism, and 1 arterithe limited clinical benefits, this research group osclerotic) for several days, and 1 patient

  • did not pursue further experimentation.
  • received 3 g/d for 3 years. Two of the patients

Other research groups, aware of the findings showed some benefit. IV levodopa (250 mg) in reserpinized rodents, also attempted to was also given to 3 of the patients, of whom restore striatal dopamine concentrations and only one of the 3 (a postencephalitic patient) relieve parkinsonian signs and symptoms using had a beneficial response. The authors conthe strategy of precursor therapy. In the 7 years cluded that levodopa had little to offer as a following the publication of Carlsson’s report, therapeutic agent in the treatment of and the work of Birkmayer and Hornykiewicz, parkinsonism.40

  • small-scale clinical investigations were carried
  • The results of studies by both Birkmayer

out in Germany, Italy, Canada, Sweden, and McGeer were particularly discouraging Finland, and the United States.33–47 For the and might have spelled the end of attempts most part, these studies used IV administration to treat PD with levodopa. Many experts, of either the levo or the racemic forms of 3,4- including Melvin Yahr and Roger Duvoisin dihydroxyphenylalanine and study designs that in the late 1960s, were unimpressed with the were either open-label or placebo-controlled.24 reported results using both D,L-3,4- Overall, the clinical results from these studies dihydroxyphenylalanine and levodopa.49,50 were not impressive for achieving relief of par- From today’s perspective, after decades of kinsonian features. During this period, consid- experience in recognizing the diversity of parerable basic neuroscience progress enhanced kinsonian signs and symptoms, disorders that knowledge about dopamine’s role in parkin- mimic PD, the impact of placebo effect on clinsonism. However, the therapeutic approach of ical trials, the importance of controlled experiadministering a dopamine precursor seemed to ments, and the need for testing long duration of fail and there was considerable skepticism in the treatment, it seems no wonder that the small

  • early 1960s.
  • doses of administered levodopa or racemic 3,4-

Birkmayer and Hornykiewicz, who made use dihydroxyphenylalanine and the insufficient of the levo form of 3,4-dihydroxyphenylalanine trials of higher doses were doomed to fail.

  • in their 1961 experiments, attempted to repli-
  • Fortunately, another mindset as to the ther-

cate their findings in subsequent studies. They apeutic challenge in PD brought renewed reported on 200 patients with parkinsonian interest in levodopa. The American pharmasymptoms who received 25-mg IV injections cologist George Cotzias initiated a series of exof levodopa that were administered once or periments with treatment strategies that twice weekly (together with an inhibitor of differed from an approach to restore striatal monoamine oxidase).48 The results of this dopaminergic neurotransmission. Instead, approach were far less encouraging than what Cotzias51 envisioned that the treatment for they previously reported. They found evidence PD needed to target the absence of neuromelfor improvement in slowed movement for only anin pigment in the substantia nigra. This 20% of the patients. While half of them showed neuropathologic finding, which was also

S6

Neurology 86 (Suppl 1) April 5, 2016

ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.

prominent in the parkinsonian and dystonic 200–300 mg every 2–4 days. The uptitration disorder induced in Chilean miners from was discontinued if optimized clinical benefit chronic exposure to manganese, led Cotzias was observed or if adverse effects developed. and colleagues to treat a group of patients with The uppermost dosage was 8 g/d if needed. PD with intramuscular injections of The study was laborious, requiring several melanocyte-stimulating hormone and oral months of in-hospital treatment and evaluaadministration of phenylalanine and 3,4- tion. The results showed at least partial dihydroxyphenylalanine (the latter 2 amino improvement for most of the patients, and acids in racemic forms). Although their treat- 10 of the 28 had “dramatic” improvement, ment hypothesis was not to replenish dopamine with another 10 classified as showing in the brain, their trial with D,L-3,4- “marked” improvement. The investigators dihydroxyphenylalanine showed dramatic effec- classified the remainder is having “moderate” tiveness, in contrast to melanocyte-stimulating or “modest” improvement in parkinsonian hormone and phenylalanine (each of which signs, and every feature of parkinsonism exacerbated tremor).6 Among 16 patients receiv- showed some response, although not uniing D,L-3,4-dihydroxyphenylalanine for treat- formly across all of the patients. To achieve ment periods ranging from 33 to 347 days, 8 these effects, the average optimal dosage was patients showed either complete or marked 5.8 g per day (ranging from 4.2 to 7.5 g/d).7

  • improvement of rigidity and tremor. The
  • With the high doses of levodopa used in

doses used ranged from 3 to 16 g/d in divided the study came adverse effects not previously doses. An additional 2 patients showed some encountered. Nausea and vomiting were improvements, and no patients worsened. common but could be prevented by the Among the adverse effects were nausea, vom- development of pharmacologic tolerance with iting, and postural lightheadedness. Cotzias the slow titration schedule. One of the paand colleagues6 observed that side effects tients showed psychic changes including seem to be more prominent with rapid irritability, anger, hostility, paranoia, and increase of daily drug intake. They also found sleeplessness. Others showed improvements that 25% of the patients developed a mild, in mental functioning that were described as transient granulocytopenia in correlation to an effect of psychic “awakening” (the topic intake of more than 200 g of the drug. The of an influential book about high-dose levosalient points that differentiated this study dopa therapy of postencephalitic parkinsonfrom previous clinical experience with levo- ism that was published in 1973 by Oliver dopa or D,L-3,4-dihydroxyphenylalanine are Sacks, Awakenings,52 followed by a Hollythe greatly increased daily intake that was wood movie with the same title in 1990, used and the sustained periods of treatment. based on the book). As continued exposure The slow buildup of dosage seems to be the to levodopa was observed by Cotzias et al.,7 critical factor permitting an adequate test for involuntary movements (dyskinesias) became

  • investigation of replacement therapy.6
  • evident in half of them (and in some instances

The outcome of the initial 1967 clinical took on relatively severe choreic or ballistic study carried out by Cotzias et al.6 at features). During the course of their second Brookhaven National Laboratories led to the study, the L-aromatic amino acid decarboxylconclusion that further studies with levodopa, ase inhibitor carbidopa was developed and instead of the racemic mixture, seemed “highly became available for some participants in warranted.” Two years later, Cotzias et al.7 re- the clinical trial. This compound, blocking ported on a group of 28 parkinsonian patients peripheral conversion of levodopa to dopatreated with levodopa. The patients were first mine, offered a synergistic action, permitting given placebo and then had levodopa intro- lower doses of levodopa to be used. On this duced in a regimen of substituting levodopa basis, the optimized intake of levodopa for placebo gradually in dosing of 3 times per tended to be much lower.

  • day. Initially, they received 100 mg. Subse-
  • The 1969 publication of clinical trial results

quent dosing, as tolerated, was increased by from the Brookhaven National Laboratories

Recommended publications
  • Kchip4a: a Biophysical Modulator of Learning from Disappointment

    Kchip4a: a Biophysical Modulator of Learning from Disappointment

    KChIP4a: a biophysical modulator of learning from disappointment Dissertation for obtaining a doctorate degree in natural sciences presented to the Faculty of Biosciences of Goethe University by Kauê Machado Costa from Belém do Pará, Brazil Frankfurt am Main (2017) (D 30) Accepted by the Faculty of Biosciences of Goethe University as a PhD dissertation Dean: Prof. Dr. Sven Klimpel 1st expert assessor: Prof. Dr. Manfred Kössl 2nd expert assessor: Prof. Dr. Jochen Roeper 3rd expert assessor: Prof. Dr. Amparo Acker-Palmer 4st expert assessor: Prof. Dr. Bernd Grünewald Date of disputation: 19.04.2018 “Exploration is in our nature. We began as wanderers, and we are wanderers still.” ― Carl Sagan, Cosmos Acknowledgements I would like to express my enduring gratitude to: Prof. Dr. Jochen Roeper for providing unwavering, outstanding and continuous support, trust, motivation, funding and fun during my stay in his lab. Prof. Dr. Gilles Laurent for having me in his lab as a rotation student and for providing very instructive comments and support as a member of my thesis committee. Prof. Dr. Manfred Kössl for being my official PhD thesis supervisor at the Biological Sciences Faculty and for providing insightful comments as a member of my thesis committee. Prof. Dr. Gaby Schneider for the highly profitable, illuminating and friendly collaboration over the entire course of my thesis. Prof. Dr. Eleanor Simpson and Prof. Dr. Eric Kandel for, in a short conversation in Columbia, providing me with the crucial yet often forgotten insight that neuroscience always needs a solid grounding in behavior. Dr. Mahalakshmi Subramaniam for teaching me in vivo neuronal recordings.
  • Levodopa-Induced Dyskinesias in Parkinson's Disease

    Levodopa-Induced Dyskinesias in Parkinson's Disease

    Neuropsychiatric Disease and Treatment Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments Panagiotis Bargiotas Abstract: Parkinson’s disease therapy is still focused on the use of L-3,4-dihydroxyphenylalanine Spyridon Konitsiotis (levodopa or L-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades. However, regardless of its Department of Neurology, University of Ioannina, Ioannina, Greece effectiveness, the long-term use of levodopa causes, in combination with disease progression, the development of motor complications termed levodopa-induced dyskinesias (LIDs). LIDs are the result of profound modifications in the functional organization of the basal ganglia circuitry, possibly related to the chronic and pulsatile stimulation of striatal dopaminergic receptors by levodopa. Hence, for decades the key feature of a potentially effective agent against LIDs has been its ability to ensure more continuous dopaminergic stimulation in the brain. The growing For personal use only. knowledge regarding the pathophysiology of LIDs and the increasing evidence on involvement of nondopaminergic systems raises the possibility of more promising therapeutic approaches in the future. In the current review, we focus on novel therapies for LIDs in Parkinson’s disease, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development. Keywords: motor fluctuations, dopaminergic/nondopaminergic systems, pharmacotherapy Introduction Parkinson’s disease (PD) is a common neurodegenerative disorder with a wide spec- trum of clinical features, including motor symptoms, gait and balance disorders, and cognitive, emotional, and behavioral deficits.
  • Rat Model of Pre-Motor Parkinson's Disease

    Rat Model of Pre-Motor Parkinson's Disease

    Rat Model of Pre-Motor Parkinson‘s Disease: Behavioral and MRI Characterization. A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Engineering by Pallavi Satish Rane 3/28/2011 Christopher H. Sotak, Ph.D. Jean A. King, Ph. D. Academic Advisor Research Advisor Professor Professor Department of Biomedical Engineering Department of Psychiatry Worcester Polytechnic Institute University of Massachusetts Medical School, Worcester George D. Pins, Ph.D. Nanyin Zhang, Ph. D. Associate Professor Assistant Professor Department of Biomedical Engineering Department of Psychiatry Worcester Polytechnic Institute University of Massachusetts Medical School, Worcester Gregory J. DiGirolamo, Ph. D. Associate Professor Department of Psychology College of Holy Cross ii Acknowledgements As the ―graduate student‖ part of my life draws to a close, I cannot help but look back and be grateful for the support of numerous friends, family members and members of the WPI and UMass community. First and foremost, I have to mention my mentors Dr. Chris Sotak and Dr. Jean King. Dr. Sotak gave me a chance to start this journey and allowed me to start working in his lab even when I was just a first yea r student. Dr. Sotak, I cannot thank you enough for your support, encouragement, guidance, and most of all, for your patience with my ―200 questions‖ attitude. You have always made me feel immensely welcome in this foreign country. You will always have a s pecial place in my heart. Dr. Jean King has guided me through. Jean, CCNI has been a second family to me and I could not have made it through some really tough times without your support and kindness.
  • 43 the Basal Ganglia

    43 the Basal Ganglia

    Back 43 The Basal Ganglia Mahlon R. DeLong THE BASAL GANGLIA CONSIST of four nuclei, portions of which play a major role in normal voluntary movement. Unlike most other components of the motor system, however, they do not have direct input or output connections with the spinal cord. These nuclei receive their primary input from the cerebral cortex and send their output to the brain stem and, via the thalamus, back to the prefrontal, premotor, and motor cortices. The motor functions of the basal ganglia are therefore mediated, in large part, by motor areas of the frontal cortex. Clinical observations first suggested that the basal ganglia are involved in the control of movement and the production of movement disorders. Postmortem examination of patients with Parkinson disease, Huntington disease, and hemiballismus revealed pathological changes in these subcortical nuclei. These diseases have three characteristic types of motor disturbances: (1) tremor and other involuntary movements; (2) changes in posture and muscle tone; and (3) poverty and slowness of movement without paralysis. Thus, disorders of the basal ganglia may result in either diminished movement (as in Parkinson disease) or excessive movement (as in Huntington disease). In addition to these disorders of movement, damage to the basal ganglia is associated with complex neuropsychiatric cognitive and behavioral disturbances, reflecting the wider role of these nuclei in the diverse functions of the frontal lobes. Primarily because of the prominence of movement abnormalities associated with damage to the basal ganglia, they were believed to be major components of a motor system, independent of the pyramidal (or corticospinal) motor system, the “extrapyramidal” motor system.
  • Current Neuropharmacology, 2017, 15, 184-194

    Current Neuropharmacology, 2017, 15, 184-194

    184 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2017, 15, 184-194 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Factor: 3.753 Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape BENTHAM SCIENCE Kenneth Blum1-6,8,11,12,14,*, Marcelo Febo1, Rajendra D. Badgaiyan7, Zsolt Demetrovics8, Thomas Simpatico2, Claudia Fahlke9, Oscar-Berman M10, Mona Li11, Kristina Dushaj11 12,13 and Mark S. Gold 1Department of Psychiatry, University of Florida College of Medicine and McKnight Brain Institute, Gainesville, FL, USA; 2Department of Psychiatry, University of Vermont, Burlington, VT, USA; 3 Division of Neuroscience Based Therapy, Summit Estates Recovery Center, Las Gatos, CA, USA; 4Dominion Diagnostics, LLC, North Kingstown, RI, USA; 5IGENE, LLC, Austin, TX, USA; 6Department of Nutrigenomics, RDSolutions, Inc., Salt Lake City, UT, USA; 7Division of Neuroimaging, Department of Psychiatry, University of Minnesota College of Medicine, Minneapolis, MN, USA; 8Department of Psychology, Eotvos Lorand University, Budapest, Hungary; 9Department of Psychology, University of Gothenburg, Göteborg, Sweden; 10Departments of Psychiatry and Anatomy & Neurobiology, Boston University School of Medicine and Boston VA Healthcare System, Boston, MA, USA; 11PATH Foundation NY, New York, NY, USA; 12Departments of Psychiatry & Behavioral Sciences, Keck School of Medicine of USC, Los Angeles, CA, USA; 13Department of Psychiatry, Washington University School of Medicine. St. Louis, MO, USA; 14Division of Neuroscience Research and Addiction Therapy, The Shores Treatment and Recovery, Port Saint Lucie, FL, USA Abstract: Background: In 1990, Blum and associates provided the first confirmed genetic link between the DRD2 polymorphisms and alcoholism.
  • The L-Dopa Story: Translational Neuroscience Ante Verbum

    The L-Dopa Story: Translational Neuroscience Ante Verbum

    Article Clinical & Translational Neuroscience January-June 2018: 1–5 ª The Author(s) 2018 The L-dopa story: Translational Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/2514183X18765401 neuroscience ante verbum journals.sagepub.com/home/ctn Hans-Peter Ludin Abstract Since almost 50 years L-Dopa is the gold standard for the treatment of patients with Parkinson’s disease (PD). For the first time, a specific chemical abnormality was found in a specific brain disorder. It has been shown that the striatal dopamine (DA) content is greatly reduced in PD patients. The substitution of DA by its precursor L-dopa greatly enhanced the quality of life of PD patients. Keywords Parkinson’s disease, dopamine, L-dopa, history In the late 60s and the early 70s of the 20th century, the metabolized to dopamine (DA) by dopa decarboxylase.4 introduction of levodopa (L-dopa) in treatments markedly It is not surprising that his contribution, published in Ger- changed the fate of patients suffering from Parkinson’s man, received little attention at the time. Holtz and Cred- disease (PD) in Western countries. It was preceded by a ner5 have injected 50 mg of L-dopa intravenously to a series of antecedents during several decades. Nowadays, volunteer, resulting merely in an increase in the pulse rate. L-dopa combined with a decarboxylase inhibitor is the gold For a long time, DA was considered as a mere meta- standard treatment for PD. This conclusion has been bolic intermediate in the formation of the catecholamines reached along a long and winding path.
  • Psychiatric Aspects of Parkinson's Disease

    Psychiatric Aspects of Parkinson's Disease

    ecnp matters NEWSLETTER NO. 4, December 2002 Looking back at Barcelona Page 3 ECNP Consensus Meeting 2002: Expectations certainly met Long-term treatment in psychi- atric and neurological diseases In the June 2002 issue of ecnp matters the Scientific Programme Committee focused with enthusiasm on certain aspects of the 15th ECNP Congress. Were Page 4-6 15th ECNP Congress those expectations met? Barcelona - October 5 - 9, 2002 David J. Nutt, chair SPC 15th ECNP Congress Page 7 rack system very impressive turnout to this new ses- Calendar ECNP events TBy common consensus the new sion, with many more delegates than track systems would seem to be a great the individual presenters could have success. Participants were guided expected to reach in an ordinary set- Page 8 through the extensive programme by ting. General Assembly Barcelona classifying the presentations into one of The quality of the presentations (after the following: some slight teething problems with the – treatment track audiovisual system) was uniformly high – clinical research track and the quality of the discussions con- – interface track firmed that this quality was well appre- – preclinical track ciated. I got the impression that the – educational track. young hot topic presenters really I received a number of unsolicited pos- enjoyed the privilege of being at the itive comments about the logical struc- ECNP Congress and some of them cer- talk through some of the issues raised announcing a lot of new cutting edge ture, the value of such a thematic tainly were very active at the congress in the particular sessions. We are wait- data.
  • Editorial Advisory Committee

    Editorial Advisory Committee

    EDITORIAL ADVISORY COMMITTEE Verne S. Caviness Bernice Grafstein Charles G. Gross Theodore Melnechuk Dale Purves Gordon M. Shepherd Larry W. Swanson (Chairperson) The History of Neuroscience in Autobiography VOLUME 2 Edited by Larry R. Squire ACADEMIC PRESS San Diego London Boston New York Sydney Tokyo Toronto This book is printed on acid-free paper. @ Copyright 91998 by The Society for Neuroscience All Rights Reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. Academic Press a division of Harcourt Brace & Company 525 B Street, Suite 1900, San Diego, California 92101-4495, USA http://www.apnet.com Academic Press 24-28 Oval Road, London NW1 7DX, UK http://www.hbuk.co.uk/ap/ Library of Congress Catalog Card Number: 98-87915 International Standard Book Number: 0-12-660302-2 PRINTED IN THE UNITED STATES OF AMERICA 98 99 00 01 02 03 EB 9 8 7 6 5 4 3 2 1 Contents Lloyd M. Beidler 2 Arvid Carlsson 28 Donald R. Griffin 68 Roger Guillemin 94 Ray Guillery 132 Masao Ito 168 Martin G. Larrabee 192 Jerome Lettvin 222 Paul D. MacLean 244 Brenda Milner 276 Karl H. Pribram 306 Eugene Roberts 350 Gunther Stent 396 Arvid Carlsson BORN: Uppsala, Sweden January 25, 1923 EDUCATION: University of Lund, M.D. ( 1951) University of Lund, Ph.D. ( 1951) APPOINTMENTS: University of Gothenburg ( 1951) Professor Emeritus, University of Gothenburg (1989) HONORS AND AWARDS: Royal Swedish Academy of Science (1975) Wolf Prize in Medicine, Israel (1979) Japan Prize (1994) Foreign Associate, Institute of Medicine, National Academy of Sciences, U.S.A.
  • Apomorphine for Parkinson’S Dise

    Apomorphine for Parkinson’S Dise

    280280 PRACTICAL NEUROLOGY Pract Neurol: first published as 10.1046/j.1474-7766.2002.00086.x on 1 October 2002. Downloaded from HOW TO DO IT apomorphine for Parkinson’s dise http://pn.bmj.com/ Andrew Lees and Kirsten Turner pomorphine was fi rst used to treat Reta Lila Weston Institute for Neurologi- behavioural vices in domesticated farm cal Studies, UCL, Windeyer Medical Insti- Aanimals in the nineteenth century and tute, 46 Cleveland St, London, UK; E-mail: is still used in veterinary medicine. It has had on September 24, 2021 by guest. Protected copyright. [email protected] a chequered history in medical therapeutics, Practical Neurology, 2, 280–286 being successfully recommended as an emetic, a sedative, a treatment for narcotic and alcohol dependence and most recently for sexual dys- function and impotence. It was fi rst proposed as a treatment for movement disorders 150 years ago, but this indication was not pursued until the 1950s when Schwab in Boston confi rmed its potential (Schwab et al. 1951). Following his demonstration that large doses of dopa improved Parkinson’s disease, George Cotzias looked for other dopamine analogues that might have complementary effects and car- ried out a series of scrupulous and fascinating experiments with apomorphine (Cotzias et al. 1970). These indicated that the effects of the drug, when administered by subcutaneous © 2002 Blackwell Science Ltd 05-pnr07-086.indd 280 11/10/2002, 11:32:19 OCTOBER 2002 281 Pract Neurol: first published as 10.1046/j.1474-7766.2002.00086.x on 1 October 2002. Downloaded from sease injection, were potent but short-lived, and that 4–6 h prior to the challenge.
  • Personalized Medicine in Parkinson's Disease: New Options For

    Personalized Medicine in Parkinson's Disease: New Options For

    Journal of Personalized Medicine Review Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments Takayasu Mishima 1, Shinsuke Fujioka 1, Takashi Morishita 2 , Tooru Inoue 2 and Yoshio Tsuboi 1,* 1 Department of Neurology, School of Medicine, Fukuoka University, 7-45-1, Nanakuma, Johnan-ku, Fukuoka 814-0180, Japan; [email protected] (T.M.); [email protected] (S.F.) 2 Department of Neurosurgery, School of Medicine, Fukuoka University, Fukuoka 814-0180, Japan; [email protected] (T.M.); [email protected] (T.I.) * Correspondence: [email protected]; Tel.: +81-92-801-1011; Fax: +81-92-865-7900 Abstract: Parkinson’s disease (PD) presents varying motor and non-motor features in each patient owing to their different backgrounds, such as age, gender, genetics, and environmental factors. Furthermore, in the advanced stages, troublesome symptoms vary between patients due to motor and non-motor complications. The treatment of PD has made great progress over recent decades and has directly contributed to an improvement in patients’ quality of life, especially through the progression of advanced treatment. Deep brain stimulation, radiofrequency, MR–guided focused ultrasound, gamma knife, levodopa-carbidopa intestinal gel, and apomorphine are now used in the clinical setting for this disease. With multiple treatment options currently available for all stages of PD, we here discuss the most recent options for advanced treatment, including cell therapy in advanced PD, from the perspective of personalized medicine. Keywords: Parkinson’s disease; deep brain stimulation; levodopa-carbidopa intestinal gel; apo- Citation: Mishima, T.; Fujioka, S.; morphine; radiofrequency; focused ultrasound; induced pluripotent stem cells; cell therapy; gene Morishita, T.; Inoue, T.; Tsuboi, Y.
  • The Discovery of Dopamine

    The Discovery of Dopamine

    The Discovery of Dopamine Dopamine as an independent neurotransmitter in the nervous system was discovered in Lund by the pharmacologist Arvid Carlsson in 1957, working at the Department of Pharmacology at Sölvegatan 10 in Lund (the current Geocentrum building). This discovery had tremendous impact on modern neuroscience research and – in combination with his later work performed at the University of Göteborg - would render him the Nobel Prize for Physiology and Medicine in 2000. The amine 3-hydroxytyramine (‘dopamine’) had earlier been identified as an intermediary in the synthesis of noradrenaline and adrenaline from tyrosine. In 1957, Arvid Carlson, Margit Lindqvist, Tor Magnusson and Bertil Waldeck, made the seminal observations that during the subsequent years would lead to the unravelling of dopamine as a transmitter in the central nervous system, independent of its role as a precursor in noradrenaline and adrenaline synthesis. In their 1957 and 1958 papers [1.2], (Carlsson et al 1957) (Carlsson et al 1958) Carlsson and co-workers made the intriguing observation that the akinetic effects of reserpine could be reversed by an intravenous injection of the dopamine (and noradrenaline) precursor, 3,4- dihydroxyphenylalanine (DOPA). The functional effect was correlated to a recovery of dopamine, but not noradrenaline, content in the brain, suggesting that depletion of dopamine, rather than noradrenaline or serotonin, was the cause of the akinetic state in reserpine-treated animals. The following year, Carlsson's students Ǻke Bertler and Evald Rosengren [3], and I. Sano and collaborators in Japan [4], reported that the bulk of the brain’s dopamine was located in the striatum (a structure containing little noradrenaline), thus providing further support for the idea that this new, putative transmitter may play a central role in the control of motor function [5].
  • Influence of Oliver Sacks on Levodopa Therapy in Early 1970S

    Influence of Oliver Sacks on Levodopa Therapy in Early 1970S

    DOI: 10.1590/0004-282X20160095 HISTORICAL NOTE Harbinger of storm: influence of Oliver Sacks on levodopa therapy in early 1970s Arauto da tempestade: a influência de Oliver Sacks sobre a terapia com levodopa no início da década de 1970 Bruno Lopes dos Santos-Lobato1,2, Vitor Tumas1,2 ABSTRACT Most known by his literary ability, the words of the neurologist Oliver Sacks (1933-2015) also had an impact on scientific community about the role of levodopa on parkinsonisms. Different from the most authors and based on his experience described on the book “Awakenings”, he had a pessimistic opinion about levodopa, which was related on many articles written by himself and colleagues in early 1970s. We reviewed the scientific contribution of Oliver Sacks associated to levodopa therapy on parkinsonisms, and how he advised caution with its complications before the majority of physicians. Keywords: Oliver Sacks, Parkinson’s disease, levodopa, dyskinesias. RESUMO Mais conhecido por sua habilidade literária, as palavras do neurologista Oliver Sacks (1933-2015) também tiveram um impacto sobre a comunidade científica a respeito do uso de levodopa nos parkinsonismos. Diferente da maioria dos autores e baseado em sua experiência única descrita no livro “Tempo de Despertar”, ele tinha uma opinião mais pessimista sobre a levodopa, que ficou relatada em uma série de artigos publicados por ele e colaboradores no início da década de 1970. Revisaremos a contribuição científica de Oliver Sacks referente ao tratamento dos parkinsonismos com levodopa, e como advertiu a cautela com as complicações decorrentes desta medicação antes da maioria dos médicos. Palavras-chave: Oliver Sacks, doença de Parkinson, levodopa, discinesias.